1. Abnormal expression of serum miR-4746-5p in liver cancer patients after interventional chemotherapy and its possible mechanism.
- Author
-
Deng K, Wang W, Chi X, Yu Y, Zhang Y, and Yuan J
- Subjects
- Humans, Male, Female, Middle Aged, Cyclin-Dependent Kinase Inhibitor p57 genetics, Cell Proliferation drug effects, Gene Expression Regulation, Neoplastic drug effects, MicroRNAs blood, MicroRNAs genetics, Liver Neoplasms drug therapy, Liver Neoplasms blood, Liver Neoplasms pathology
- Abstract
Interventional chemotherapy is a common operation in the clinical treatment of liver cancer. The aim of this study was to investigate the expression and molecular mechanism of serum miR-4746-5p in liver cancer patients before and after interventional chemotherapy. The levels of miR-4746-5p and CDKN1C in serum samples from liver cancer patients were detected using real-time fluorescence quantitative polymerase chain reaction. Receiver operating characteristic curves revealed the diagnostic value of miR-4746-5p in tumors. Differences in clinical indicators between liver cancer patients and healthy controls were assessed using Pearson correlation analysis. Luciferase reporter gene assays confirmed the targeted interaction between miR-4746-5p and CDKN1C. In vitro cellular assays were validated by Cell Counting Kit-8, Transwell assay, and chemoresistance assay. Serum miR-4746-5p levels were increased in liver cancer patients but were downregulated after chemotherapy intervention. CDKN1C expression showed the opposite trend. Low levels of miR-4746-5p mediated cell growth and metastasis by targeting and negatively regulating CDKN1C expression, while silencing CDKN1C restored cell activity. Inhibition of miR-4746-5p reduced chemoresistance, while downregulation of CDKN1C affected cell sensitivity. miR-4746-5p may be a potential therapeutic factor for liver cancer diagnosis and interventional chemotherapy., (© 2024 International Union of Biochemistry and Molecular Biology, Inc.)
- Published
- 2024
- Full Text
- View/download PDF